These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 27484492)

  • 1. Pre-Clinical Study of a Novel Recombinant Botulinum Neurotoxin Derivative Engineered for Improved Safety.
    Vazquez-Cintron E; Tenezaca L; Angeles C; Syngkon A; Liublinska V; Ichtchenko K; Band P
    Sci Rep; 2016 Aug; 6():30429. PubMed ID: 27484492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuronal targeting, internalization, and biological activity of a recombinant atoxic derivative of botulinum neurotoxin A.
    Pellett S; Tepp WH; Stanker LH; Band PA; Johnson EA; Ichtchenko K
    Biochem Biophys Res Commun; 2011 Feb; 405(4):673-7. PubMed ID: 21284937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rat Digit Abduction Score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis.
    Broide RS; Rubino J; Nicholson GS; Ardila MC; Brown MS; Aoki KR; Francis J
    Toxicon; 2013 Sep; 71():18-24. PubMed ID: 23707612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6.
    Moritz MS; Tepp WH; Bradshaw M; Johnson EA; Pellett S
    mSphere; 2018 Oct; 3(5):. PubMed ID: 30355669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intramuscular Botulinum Neurotoxin Serotypes E and A Elicit Distinct Effects on SNAP25 Protein Fragments, Muscular Histology, Spread and Neuronal Transport: An Integrated Histology-Based Study in the Rat.
    Martin V; Carre D; Bilbault H; Oster S; Limana L; Sebal F; Favre-Guilmard C; Kalinichev M; Leveque C; Boulifard V; George C; Lezmi S
    Toxins (Basel); 2024 May; 16(5):. PubMed ID: 38787077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions.
    Baskaran P; Lehmann TE; Topchiy E; Thirunavukkarasu N; Cai S; Singh BR; Deshpande S; Thyagarajan B
    Toxicon; 2013 Sep; 72():71-80. PubMed ID: 23810945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atoxic derivative of botulinum neurotoxin A as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasm.
    Vazquez-Cintron EJ; Vakulenko M; Band PA; Stanker LH; Johnson EA; Ichtchenko K
    PLoS One; 2014; 9(1):e85517. PubMed ID: 24465585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
    Adler M; Keller JE; Sheridan RE; Deshpande SS
    Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A dileucine in the protease of botulinum toxin A underlies its long-lived neuroparalysis: transfer of longevity to a novel potential therapeutic.
    Wang J; Zurawski TH; Meng J; Lawrence G; Olango WM; Finn DP; Wheeler L; Dolly JO
    J Biol Chem; 2011 Feb; 286(8):6375-85. PubMed ID: 21138836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Globular chitosan prolongs the effective duration time and decreases the acute toxicity of botulinum neurotoxin after intramuscular injection in rats.
    Sergeevichev DS; Krasilnikova AA; Strelnikov AG; Fomenko VV; Salakhutdinov NF; Romanov AB; Karaskov AM; Pokushalov EA; Steinberg JS
    Toxicon; 2018 Mar; 143():90-95. PubMed ID: 29371111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Holotoxin Activity of Botulinum Neurotoxin Subtype A4 Originating from a Nontoxigenic Clostridium botulinum Expression System.
    Bradshaw M; Tepp WH; Whitemarsh RC; Pellett S; Johnson EA
    Appl Environ Microbiol; 2014 Dec; 80(23):7415-22. PubMed ID: 25239905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translocation domain of botulinum neurotoxin A subtype 2 potently induces entry into neuronal cells.
    Kohda T; Tsukamoto K; Torii Y; Kozaki S; Mukamoto M
    Microbiol Immunol; 2020 Jul; 64(7):502-511. PubMed ID: 32301520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A.
    Keller JE; Neale EA
    J Biol Chem; 2001 Apr; 276(16):13476-82. PubMed ID: 11278807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-distance retrograde effects of botulinum neurotoxin A.
    Antonucci F; Rossi C; Gianfranceschi L; Rossetto O; Caleo M
    J Neurosci; 2008 Apr; 28(14):3689-96. PubMed ID: 18385327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A substrate sensor chip to assay the enzymatic activity of Botulinum neurotoxin A.
    Lévêque C; Ferracci G; Maulet Y; Grand-Masson C; Blanchard MP; Seagar M; El Far O
    Biosens Bioelectron; 2013 Nov; 49():276-81. PubMed ID: 23787358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Onset dynamics of type A botulinum neurotoxin-induced paralysis.
    Lebeda FJ; Adler M; Erickson K; Chushak Y
    J Pharmacokinet Pharmacodyn; 2008 Jun; 35(3):251-67. PubMed ID: 18551355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exchanging the minimal cell binding fragments of tetanus neurotoxin in botulinum neurotoxin A and B impacts their toxicity at the neuromuscular junction and central neurons.
    Höltje M; Schulze S; Strotmeier J; Mahrhold S; Richter K; Binz T; Bigalke H; Ahnert-Hilger G; Rummel A
    Toxicon; 2013 Dec; 75():108-21. PubMed ID: 23817019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A SNAP-25 cleaving chimera of botulinum neurotoxin /A and /E prevents TNFα-induced elevation of the activities of native TRP channels on early postnatal rat dorsal root ganglion neurons.
    Nugent M; Yusef YR; Meng J; Wang J; Dolly JO
    Neuropharmacology; 2018 Aug; 138():257-266. PubMed ID: 29906413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute and chronic effects of botulinum neurotoxin a on the mammalian neuromuscular junction.
    Baskaran P; Thyagarajan B
    Muscle Nerve; 2014 Aug; 50(2):206-15. PubMed ID: 24218344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety.
    Roger Aoki K
    Toxicon; 2002 Jul; 40(7):923-8. PubMed ID: 12076646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.